Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting
Protagonist Therapeutics announced that final data from the Phase 2 REVIVE study of rusfertide in polycythemia vera will be presented at the 66th Annual American Society of Hematology (ASH) Meeting. The presentation, titled 'Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV),' will be delivered by Dr. Aaron Gerds from Cleveland Clinic on December 9, 2024, in San Diego.
Protagonist Therapeutics ha annunciato che i dati finali dello studio di Fase 2 REVIVE su rusfertide nella poliocitemia vera saranno presentati durante il 66° Congresso Annuale della Società Americana di Ematologia (ASH). La presentazione, intitolata 'Risultati Finali dello Studio di Fase 2 Revive che Indaga il Mimetrico dell’Epcidina Rusfertide nei Pazienti con Poliocitemia Vera (PV),' sarà tenuta dal Dr. Aaron Gerds della Cleveland Clinic il 9 dicembre 2024 a San Diego.
Protagonist Therapeutics anunció que los datos finales del estudio de Fase 2 REVIVE sobre rusfertide en la policitemia vera se presentarán en la 66ª Reunión Anual de la Sociedad Americana de Hematología (ASH). La presentación, titulada 'Resultados Finales del Estudio de Fase 2 Revive que Investiga el Mimético de Hepcidina Rusfertide en Pacientes con Policitemia Vera (PV),' será presentada por el Dr. Aaron Gerds de la Cleveland Clinic el 9 de diciembre de 2024 en San Diego.
프로타고니스트 제약은 러스퍼타이드의 다혈구증가증에 대한 2상 REVIVE 연구의 최종 데이터를 66회 미국 혈액학회(ASH) 연례 회의에서 발표할 것이라고 발표했습니다. '다혈구증가증(PV) 환자에서 헤프시딘 유사체 러스퍼타이드에 대한 2상 Revive 연구의 최종 결과'라는 제목의 발표는 2024년 12월 9일 샌디에이고에서 클리블랜드 클리닉의 아론 거드 박사에 의해 진행될 예정입니다.
Protagonist Therapeutics a annoncé que les données finales de l'étude de Phase 2 REVIVE sur rusfertide dans la polycythémie vera seront présentées lors de la 66e Réunion Annuelle de la Société Américaine d'Hématologie (ASH). La présentation, intitulée 'Résultats Finaux de l'Étude de Phase 2 Revive sur le Mimétique de l'Hépcidine Rusfertide chez les Patients atteints de Polycythémie Vera (PV),' sera faite par le Dr. Aaron Gerds de la Cleveland Clinic le 9 décembre 2024 à San Diego.
Protagonist Therapeutics gab bekannt, dass die finalen Daten der Phase-2-REVIVE-Studie zu rusfertide bei Polycythaemia vera beim 66. jährlichen Treffen der American Society of Hematology (ASH) präsentiert werden. Die Präsentation mit dem Titel 'Finale Ergebnisse der Phase-2-Revive-Studie zur Untersuchung des Hepcidin-Mimetikum Rusfertide bei Patienten mit Polycythaemia Vera (PV)' wird von Dr. Aaron Gerds von der Cleveland Clinic am 9. Dezember 2024 in San Diego gehalten.
- None.
- None.
NEWARK, CA / ACCESSWIRE / November 5, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that final data from the Phase 2 REVIVE study with rusfertide in polycythemia vera will be the focus of a poster presentation at the 66th Annual American Society of Hematology (ASH) Annual Meeting being held in San Diego from December 7-10, 2024.
ASH Presentation Details:
Presenting author: Aaron Gerds, MD (Cleveland Clinic)
Publication Number: 4559
Title: Final Results from the Phase 2 Revive Study Investigating the Hepcidin Mimetic Rusfertide in Patients with Polycythemia Vera (PV)
Session Name: 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Poster III
Session Date: Monday, December 9, 2024
Presentation Time: 6:00 PM - 8:00 PM PST
Location: San Diego Convention Center, Halls G-H
About Protagonist
Protagonist Therapeutics is a late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are in advanced Phase 3 clinical development, with potential New Drug Application submissions to the FDA in 2025. JNJ-2113 is an oral Interleukin-23 receptor (IL-23R) antagonist licensed to Johnson & Johnson (JNJ) in Phase 3 development for psoriasis and nearing completion of Phase 2b development for ulcerative colitis. Following JNJ-2113's joint discovery by Company and JNJ scientists pursuant to the companies' IL-23R collaboration, the Company was primarily responsible for development of JNJ-2113 through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide is a mimetic of the natural hormone hepcidin in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered into in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of promising pre-clinical discovery programs addressing validated targets, including IL-17, obesity and oral hepcidin.
More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company's website at https://www.protagonist-inc.com/.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the potential benefits of JNJ-2113 and rusfertide, the timing of JNJ-2113 and rusfertide clinical trials, and timing of developments and announcements in our discovery programs. In some cases, you can identify these statements by forward-looking words such as "anticipate," "believe," "may," "will," "expect," or the negative or plural of these words or similar expressions. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, our ability to develop and commercialize our product candidates, our ability to earn milestone payments under our collaboration agreements with Janssen and Takeda, our ability to use and expand our programs to build a pipeline of product candidates, our ability to obtain and maintain regulatory approval of our product candidates, our ability to operate in a competitive industry and compete successfully against competitors that have greater resources than we do, and our ability to obtain and adequately protect intellectual property rights for our product candidates. Additional information concerning these and other risk factors affecting our business can be found in our periodic filings with the Securities and Exchange Commission, including under the heading "Risk Factors" contained in our most recently filed periodic reports on Form 10-K and Form 10-Q filed with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.
Investor Relations Contact
Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com
Media Relations Contact
Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com
+1 833 500 0061
SOURCE: Protagonist Therapeutics
View the original press release on accesswire.com
FAQ
When will Protagonist Therapeutics (PTGX) present the final REVIVE Phase 2 study data at ASH 2024?
What is the focus of Protagonist Therapeutics' (PTGX) REVIVE Phase 2 study presentation at ASH 2024?
Who will present Protagonist Therapeutics' (PTGX) REVIVE Phase 2 study data at ASH 2024?
